Results from the analysis of the NRG Oncology RTOG 1005 clinical trial data concluded that treating patients with early-stage, high-risk breast cancer with a supplemental radiation boost to the surgical cavity concurrently during hypo-fractionated whole breast irradiation for a three-week treatment course was not considered inferior to treating patients over several weeks with conventional whole breast irradiation and a sequential boost following lumpectomy. These results were recently presented during the Plenary Session of the American Society for Radiation Oncology Annual Meeting in October 2022.